摘要
目的对目前国内外去甲肾上腺素治疗休克的系统评价/meta分析(SR/MA)的方法学质量和报告质量进行评价。方法通过检索万方数据知识服务平台、中国生物医学文献数据库、维普中文期刊服务平台、中国知网学术文献总库和PubMed文献数据库,检索时限:从建库至2020年6月。分别采用AMSTAR量表和PRISMA条目对最终纳入的文献进行方法学质量评价和报告质量评价。结果7篇研究符合纳入标准。AMSTAR平均得分(7.86±1.25)分,PRISMA平均得分(21.86±1.33)分。主要存在问题在前期方案注册、其他分析、局限性和研究组间的偏倚、未报告资金来源方面。结论目前国内外去甲肾上腺素治疗休克的SR/MA分析质量尚可,但仍需进一步提高方法学水平并规范报告,以期为循证决策提供高质量的证据。
Objective To evaluate the methodological quality and reporting quality of the systematic review/meta analysis(SR/MA)of norepinephrine in shock treatment at home and abroad.Methods Wanfang Data Knowledge Service Platform,China Biomedical Literature Database,VIP Chinese Journal Service Platform,China National Knowledge Infrastructure Academic Literature Database and PubMed Literature Database were searched,and the retrieval time was from the inception to June 2020.The AMSTAR scale and the PRISMA checklist were used to evaluate the methodological quality and report quality of the final included literatures.Results Seven studies met the inclusion criteria.The average score of AMSTAR was(7.86±1.25)scores and the average score of PRISMA was(21.86±1.33)scores.The main problems were in the areas of early programme registration,other analyses,limitations and bias between research groups,and unreported funding sources.Conclusion At present,the SR/MA analysis of norepinephrine for shock at home and abroad is of good quality.However,further improvement of methodology and standardized reporting are needed in order to provide high-quality evidence for evidence-based decision-making.
作者
姚金
姚冲
杨水新
姚晓丽
YAO Jin;YAO Chong;YANG Shuixin;YAO Xiaoli(Department of Pharmacy,Huzhou Central Hospital,Zhejiang Province,Huzhou313000,China;Drug PhaseⅠClinical Trial Center,Huzhou Central Hospital,Zhejiang Province,Huzhou313000,China;Department of Emergency,Huzhou Central Hospital,Zhejiang Province,Huzhou313000,China)
出处
《中国医药导报》
CAS
2021年第7期99-103,共5页
China Medical Herald
基金
浙江省医药卫生科技计划项目(2018ZH041)。
作者简介
通讯作者:姚晓丽(1981.10-),女,副主任护师,研究方向:急诊护理学。
